Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Ophthalmology
Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...
Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development
Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...
Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...
Ocumension Therapeutics Gains CDE Approval for Phase III Presbyopia Trial
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation...
Harrow Signs Licensing Deal for Formosa’s Byqlovi in US Market
US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced...
Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center
China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...
Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment
Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...
StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...
Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...
Bayer’s Eylea 8 mg Close to EU Approval for Longer Treatment Intervals
German pharmaceutical giant Bayer (ETR: BAYN) announced that the European Medicines Agency’s (EMA) Committee for...
Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...
NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment
China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...
Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
Zhaoke Ophthalmology’s Cyclosporine Eye Gel NDA Accepted by NMPA
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that the New Drug Application (NDA) for its...
Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...
Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...